-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Bamlanivimab
| Category | SARS-CoV |
| CAS | 2423943-37-5 |
| Description | Bamlanivimab is a monoclonal antibody granted Emergency Use Authorization (EUA) in November 2020 by FDA for COVID-19 therapy. Bamlanivimab is directed against the spike protein of SARS-CoV-2, designed to block the virus' attachment and entry into human cells. |
Product Information
| Synonyms | Anti-Human SARS-CoV-2 |
| Molecular Weight | 510.4 |
| Molecular Formula | C22H28Cl2F3N3OS |
| Canonical SMILES | C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO.Cl.Cl |
| Appearance | Liquid |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
